by Genetic Engineering and Biotechnology News
If you want to know if a medical field is progressing, you can start by checking a couple of obvious indicators: the number of clinical trials, and the growth projections offered by market researchers. Both of these indicators suggest that regenerative medicine is moving smartly. Last January, at the 2023 Cell and Gene State of the Industry Briefing, the Alliance for Regenerative Medicine’s CEO, Timothy D. Hunt, said that more than 2,200 active clinical trials in regenerative medicine were in progress. And last February, Grand View Research announced that it had projected that the regenerative medicine market would sustain a growth rate of 15.7%, and that the market would be worth $180 billion by 2030.
There is yet another indicator: The speed with which a field widens its scope. Even though regenerative medicine is fairly new—the field is generally considered to have started with the stem cell advances of the 1990s and 2000s—it now encompasses a broad range of activities. According to the Alliance for Regenerative Medicine, these activities include “gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.”
Read More – Click to view full article
